Levetiracetam , ≥99% , 102767-28-2

Synonym(s):
(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide;2(S)-(2-Oxopyrrolidin-1-yl)butyramide;Levetiracetam

CAS NO.：102767-28-2

Empirical Formula: C8H14N2O2

Molecular Weight: 170.209

MDL number: MFCD03265610

EINECS: 600-348-9

PRODUCT Properties

• Melting point: 118-119°C
• alpha: -89.7 º
• Flash point: 9℃
• storage temp.: 2-8°C
• solubility: H2O: >5mg/mL
• form: powder
• color: white
• optical activity: [α]/D -90±5°, c = 1 in acetone
• BCS Class: 3
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
• InChI: InChI=1/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/s3
• InChIKey: HPHUVLMMVZITSG-UHFFFAOYSA-N
• SMILES: C(N)(=O)[C@@H](N1CCCC1=O)CC |&1:3,r|
• CAS DataBase Reference: 102767-28-2(CAS DataBase Reference)

Description and Uses

Levetiracetam was first introduced in the US as an adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. This second-generation analog of piracetam can be prepared by condensation of (S)-2-aminobutyramide with 4-chlorobutyryl chloride. Although its mechanism of action is not well established, it was shown that [³H]-levetiracetam reversibly binds to a specific site predominantly present in the membranes of the brain. Unlike conventional anticonvulsants such as phenytoin, carbamazepine, valproic acid, phenobarbital, diazepam and clonazepam, compounds structurally-related to levetiracetam, such as piracetam and aniracetam, also have affinity for this site. Levetiracetam reveals a broad and unique profile in animal seizure models, including promising antiepileptogenic properties. Besides being rapidly and almost completely absorbed in man (oral bioavailability>95%), it possesses a favorable pharmacokinetic profile since it is not hepatically metabolized but only partly hydrolized into the inactive carboxylic acid by enzymes in a number of tissues including blood cells, it is minimally bound to plasma proteins (<10%) and does not inhibit or induce hepatic enzymes. Therefore levetiracetam has a low potential for drug interaction, providing a useful alternative as adjunctive therapy to treat seizures refractory to conventional anticonvulsants.

Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H319
• Precautionary statements: P301+P312+P330-P305+P351+P338
• Hazard Codes: Xn,T,F
• Risk Statements: 22-36-39/23/24/25-23/24/25-11
• Safety Statements: 26-45-36/37-16-7
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 3
• RTECS: UX9656166
• HS Code: 29337900
• Hazardous Substances Data: 102767-28-2(Hazardous Substances Data)
• Toxicity: LD50 in male mice, male rats (mg/kg): 1081, 1038 i.v. (Gobert, 1990)